TXRH (NASDAQ:TXRH) Target Lowered by Morgan Stanley to $105.00

StockMarketDaily.co reports: stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by   Morgan Stanley on 10/13/2021. In a note to investors, the firm issued a new target price of $105.00. The analysts previously had $106.00 target price.

View More TXRH (NASDAQ:TXRH) Target Lowered by Morgan Stanley to $105.00

PTGX (NASDAQ:PTGX) Target Raised by JMP Securities to $60.00

StockMarketDaily.co reports: Protagonist Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Protagonist Therapeutics stock Target Raised by   JMP Securities on 10/13/2021. In a note to investors, the firm issued a new target price of $60.00. The analysts previously had $47.00 target price.

View More PTGX (NASDAQ:PTGX) Target Raised by JMP Securities to $60.00

Protagonist Therapeutics (NASDAQ:PTGX) Target Raised by SVB Leerink LLC to $50.00

StockMarketDaily.co reports: Protagonist Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Protagonist Therapeutics stock Target Raised by   SVB Leerink LLC on 10/12/2021. In a note to investors, the firm issued a new target price of $50.00. The analysts previously had $35.00 target price.

View More Protagonist Therapeutics (NASDAQ:PTGX) Target Raised by SVB Leerink LLC to $50.00

Protagonist Therapeutics (PTGX) Upgraded by Northland Securities to Outperform

Protagonist Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Protagonist Therapeutics Upgraded by Northland Securities on 10-11-21. In a note to investors, the firm issued a new rating of Outperform. The analysts previously had rating of Market Perform.

View More Protagonist Therapeutics (PTGX) Upgraded by Northland Securities to Outperform